Literature DB >> 20412339

Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer.

María Fernanda García1, Salomé González-Reyes, Luis Ovidio González, Sara Junquera, Nana Berdize, José Manuel Del Casar, María Medina, Francisco José Vizoso.   

Abstract

Studies on metastasic lesions from human carcinomas are scarce. Therefore there is a need for such studies to identify the expression of the biological factors that will help in the assessment of the natural history of breast cancer. Here an immunohistochemical study was performed using tissue arrays and specific antibodies against matrix metalloproteinases (MMPs)-1, 2, 7, 9, 11, 13, 14 and tissue inhibitors of metalloproteases (TIMPs)-1, 2 and 3 in 39 patients with breast cancer. Specimens from 39 patients with node-positive carcinomas were examined and the analysis was performed at the central core of the tumour, at the invasive front, and in the metastasic axillary lymph nodes (MALNs). Global expression of MMP-1, 7 and 14, TIMP-1, and 3, were significantly higher at the centre of the tumour compared with the invasive front or the MALNs. Significantly higher expression of MMP-7 and 14, and TIMP-3, by fibroblast-like cells and mononuclear inflammatory cells (MICs) was seen in MALNs. In addition, in the tumour centre, the expression of MMP-11 and TIMP-1 and 2 by MICs, as well as TIMP-2 expression by fibroblast-like cells, were associated significantly with the occurrence of distant metastasis. In contrast, TIMP-3 expression by tumour cells or by fibroblast-like cells in this same tumour locations, as well as TIMP-1 expression by fibroblast-like cells at the invasive front, were associated significantly with poor prognosis. However, the expression of all of these biological factors in MALNs was not associated with the development of distant metastasis. Our data suggest that there is prognostic relevance to the expression of MMPs and TIMPs in the stromal cells of primary tumours, rather than to the expression of these enzymes in MALNs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412339      PMCID: PMC2962891          DOI: 10.1111/j.1365-2613.2010.00709.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  58 in total

Review 1.  Matrix metalloproteinases in tumor invasion and metastasis.

Authors:  I Stamenkovic
Journal:  Semin Cancer Biol       Date:  2000-12       Impact factor: 15.707

2.  The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis.

Authors:  M Abdel-Ghany; H C Cheng; R C Elble; B U Pauli
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

3.  The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer.

Authors:  P Behrens; M Rothe; A Wellmann; J Krischler; N Wernert
Journal:  J Pathol       Date:  2001-05       Impact factor: 7.996

4.  Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.

Authors:  J L Jones; P Glynn; R A Walker
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

5.  Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.

Authors:  G Davies; W G Jiang; M D Mason
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

6.  Generation and degradation of human endostatin proteins by various proteinases.

Authors:  M Ferreras; U Felbor; T Lenhard; B R Olsen; J Delaissé
Journal:  FEBS Lett       Date:  2000-12-15       Impact factor: 4.124

7.  Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.

Authors:  B S Nielsen; F Rank; J M López; M Balbin; F Vizoso; L R Lund; K Danø; C López-Otín
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

8.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1.

Authors:  V Noë; B Fingleton; K Jacobs; H C Crawford; S Vermeulen; W Steelant; E Bruyneel; L M Matrisian; M Mareel
Journal:  J Cell Sci       Date:  2001-01       Impact factor: 5.285

Review 9.  Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.

Authors:  M J Duffy; T M Maguire; A Hill; E McDermott; N O'Higgins
Journal:  Breast Cancer Res       Date:  2000-06-07       Impact factor: 6.466

10.  Study of matrix metalloproteinases and their inhibitors in breast cancer.

Authors:  F J Vizoso; L O González; M D Corte; J C Rodríguez; J Vázquez; M L Lamelas; S Junquera; A M Merino; J L García-Muñiz
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

View more
  14 in total

1.  Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer.

Authors:  Diaa Al-Raawi; Helal Abu-El-Zahab; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Int J Clin Exp Med       Date:  2011-10-11

Review 2.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

3.  Specific upregulation of RHOA and RAC1 in cancer-associated fibroblasts found at primary tumor and lymph node metastatic sites in breast cancer.

Authors:  Patricia Bortman Rozenchan; Fatima Solange Pasini; Rosimeire A Roela; Maria Lúcia Hirata Katayama; Fiorita Gonzáles Lopes Mundim; Helena Brentani; Eduardo C Lyra; Maria Mitzi Brentani
Journal:  Tumour Biol       Date:  2015-07-05

4.  A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.

Authors:  Diyuan Xue; Benjamin Moon; Jing Liao; Jingya Guo; Zhuangzhi Zou; Yanfei Han; Shuaishuai Cao; Yang Wang; Yang-Xin Fu; Hua Peng
Journal:  Sci Immunol       Date:  2022-01-07

5.  Matrix Metalloproteinase Responsive, Proximity-activated Polymeric Nanoparticles for siRNA Delivery.

Authors:  Hongmei Li; Shann S Yu; Martina Miteva; Christopher E Nelson; Thomas Werfel; Todd D Giorgio; Craig L Duvall
Journal:  Adv Funct Mater       Date:  2013-06-25       Impact factor: 18.808

6.  A reconstructed metastasis model to recapitulate the metastatic spread in vitro.

Authors:  Mukti R Parikh; Kayla E Minser; Laura M Rank; Carlotta A Glackin; Julia Kirshner
Journal:  Biotechnol J       Date:  2014-07-07       Impact factor: 4.677

7.  MMP-1 expression has an independent prognostic value in breast cancer.

Authors:  Pia Boström; Mirva Söderström; Tero Vahlberg; Karl-Ove Söderström; Peter J Roberts; Olli Carpén; Pirkko Hirsimäki
Journal:  BMC Cancer       Date:  2011-08-11       Impact factor: 4.430

8.  The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.

Authors:  Heloisa Helena Milioli; Renato Vimieiro; Carlos Riveros; Inna Tishchenko; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

Review 9.  Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series.

Authors:  Maria Aparecida Azevedo Koike Folgueira; Simone Maistro; Maria Lucia Hirata Katayama; Rosimeire Aparecida Roela; Fiorita Gonzales Lopes Mundim; Suely Nanogaki; Geertruida H de Bock; M Mitzi Brentani
Journal:  Biosci Rep       Date:  2013-12-12       Impact factor: 3.840

10.  TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.

Authors:  Charlotte Levin Tykjær Jørgensen; Christina Bjerre; Bent Ejlertsen; Karsten D Bjerre; Eva Balslev; Annette Bartels; Nils Brünner; Dorte L Nielsen
Journal:  BMC Cancer       Date:  2014-05-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.